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Available online 5 March 2016Inﬂammation is an important factor contributing to developmental brain injury in preterm infants. Although tumor
necrosis factor-inducible gene 6 protein (TSG-6) has immunomodulatory effects in several inﬂammatory conditions
of adult animals, nothing is currently known about the role of TSG-6 in the developing brain, its impact on perinatal
inﬂammation and its therapeutic potential. The aim of the current work was 1) to characterize the developmental ex-
pression of TSG-6 in the newborn rat brain, 2) to evaluate the impact of LPS exposure on TSG-6 expression and 3) to
assess the therapeutic potential of exogenous TSG-6 administration. Brain hemispheres of healthyWistar rats (postna-
tal day 1–postnatal day 15 (P1–P15))were evaluatedwith regard to the physiological expression of TSG-6. LPS-treated
rats (0.25mg/kg LPS i.p. on P3)were analyzed for inﬂammation-induced changes in TSG-6 and cytokine expression. To
evaluate whether exogenous recombinant human (rh)TSG-6 affects inﬂammation-induced brain injury, newborn
Wistar rats, exposed to LPS on P3, were treated with rhTSG-6 i.p. (four repetitive doses of 2.25 mg/kg every 12 h,
ﬁrst dose 3 h before LPS injection). PCR, Western blotting and multiplex ELISA were performed according to standard
protocols. TSG-6 is physiologically expressed in the developing brain with a linear increase in expression from P1 to
P15 at the mRNA level. At P6, regional differences in TSG-6 expression in the cortex, thalamus and striatumwere de-
tectedatmRNAandprotein level. Furthermore, TSG-6geneexpressionwas signiﬁcantly increasedby inﬂammation(in-
ducedbyLPS treatment). Combined treatmentwith LPS andTSG-6vs. LPS exposure alone, resulted in signiﬁcant down-
regulation of cleaved caspase-3, amarker of apoptosis and neuronal plasticity. In addition, several inﬂammatory serum
markers were decreased after TSG-6 treatment. Finally, TSG-6 is physiologically expressed in the developing brain.
Changes of TSG-6 expression associated with inﬂammation suggest a role of TSG-6 in neuroinﬂammation. Reduction
of cleaved caspase-3 by TSG-6 treatment demonstrates the putative neuroprotective potential of exogenous TSG-6 ad-
ministration in inﬂammation-induced developmental brain injury.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Tumor necrosis factor-inducible gene 6 protein1. Background
The report for disability-adjusted life years, based on data from the
Global Burden of Disease Study 2010, ranks pretermbirth complications
at #8 worldwide, which is an improvement compared to #3 in 1990.
Statistics for years of life lost show similar results with a change from
#3 in 1990 to #7 in 2010 (Murray et al., 2012). Thus, modern therapeu-
tic strategies and social programs, most prominently the millennium
development goals, have achieved signiﬁcant improvements. Neverthe-
less, the impact of preterm birth complications on global health is still
very high and requires further improvements. Even though the rate ofen, Hufelandstrasse 55, 45147
. This is an open access article underpretermbirths is increasing among neonatalmortalities, overall mortal-
ity has declined over the past three decades. But with increasing surviv-
al rates of immature neonates, the absolute number of babies suffering
morbidity is rising (Wen et al., 2004; Saigal and Doyle, 2008). The or-
gans most affected by prematurity are the brain (Rees and Inder,
2005) and the lung (Jobe and Bancalari, 2001). Most important for
long-term prognosis of brain involvement is the Encephalopathy of Pre-
maturity (Volpe, 2009),which comprises two severe neurological disor-
ders: periventricular leukomalacia and neuronal/axonal disease. Long-
term sequels are motoric deﬁcits up to cerebral palsy, sensory impair-
ment of the auditory and visual system and mental disability
(Larroque et al., 2008; Saigal and Doyle, 2008). The etiology of Enceph-
alopathy of Prematurity is multi-factorial with known reasons being:
drugs, hypoxia & ischemia, hyperoxia and infection/inﬂammation. In
this study, we focused on infection/inﬂammation.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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proach to speciﬁcally tackle the pathophysiology of inﬂammation-
induced developmental brain injury is not yet available (Favrais
et al., 2014). Interestingly mesenchymal stem cells (MSCs) have
been proposed to be beneﬁcial in many inﬂammatory diseases, in-
cluding developmental brain injury (Castillo-Melendez et al.,
2013). MSCs secrete the anti-inﬂammatory protein TSG-6, which
has been suggested to be responsible for a signiﬁcant part of the ben-
eﬁcial effects of MSCs. For example, this was shown for models of
myocardial infarction (Lee et al., 2009), acute lung injury (Danchuk
et al., 2011) and skin wound healing (Qi et al., 2014).
Multiple functions of TSG-6 have been implied, including modula-
tion of the extracellular matrix (Wisniewski et al., 1996; Baranova
et al., 2011; Sanggaard et al., 2010), as well as direct cell interactions
(Choi et al., 2011). Nevertheless, current knowledge about the physio-
logical function of TSG-6 is still limited. It has been demonstrated to
be essential during ovulation (Fülöp et al., 1997; Fülöp et al., 2003;
Richards, 2005) and to be important in maintaining the physiological
architecture of skin (Tan et al., 2011). Furthermore TSG-6 has strong
anti-inﬂammatory properties, which have been intensively investigated
in models of rheumatoid arthritis (Bárdos et al., 2001; Mindrescu et al.,
2002). To date the role of TSG-6 in the developing brain remains
unclear.
The aim of the current study was to evaluate 1) the developmental
expression of TSG-6 in the neonatal rat brain, 2) the role of TSG-6 in
perinatal inﬂammation with special focus on neuroinﬂammation, and
3) the effect of exogenous administration of TSG-6 on inﬂammation-
induced brain injury using an established rat model (Prager et al.,
2013; Brehmer et al., 2012).2. Methods
All animal experiments were performed in accordancewith interna-
tional guidelines for good laboratory practice and institutional guide-
lines of the University Hospital Essen and were approved by the
animal welfare committees of North Rhine Westphalia.2.1. Animal treatment
Wistar rats, provided by the central animal facility of the Univer-
sity Hospital Essen, were used for all animal experiments. Develop-
mental analysis was performed on healthy rats, decapitated on P1,
P3, P5, P7, P9, P11, P13 or P15. Analysis of the impact of inﬂammation
on neonatal brain development was performed on rats, treated on P3
with 0.25 mg/kg of LPS (Sigma-Aldrich) i.p. and decapitated on
P3 + 0–24 h, P6 and P11. To investigate the pharmacological effects
of recombinant human TSG-6 (rhTSG-6), rats were treated with four
repetitive doses of 2.25 mg/kg rhTSG-6 every 12 h beginning on P3
(ﬁrst dose 3 h prior to LPS injection) and decapitated on P3 + 6 h
and P5.2.2. Tissue collection
Animals received an overdose of chloral hydrate (200 mg of chloral
hydrate per kg body weight in 0.1 ml injection volume per 10 g body
weight) and were transcardially perfused with sterile PBS (except ani-
mals treated with LPS and decapitated on P3 + 0–24 h). Blood was col-
lected from the right atrium before perfusion. Serumwas prepared after
clotting in uncoated tubes by centrifuging at 3000g for 5 min. Brain tis-
sue was obtained by careful opening of the cranial cavity with subse-
quent brain extraction. Hemispheres or micro-dissected cortex,
thalamus and striatum were isolated, snap-frozen in liquid nitrogen
and stored at−80°C.2.3. Western blotting
Protein from snap-frozen tissue was isolated by dissolving in RIPA-
buffer (Sigma Life Science), containing PMFS (Sigma Life Science) and
cOmplete Mini, Protease inhibitor cocktail (Roche). Cell compartments
were centrifuged at 3000g for 10 min to separate the nuclei fraction
and supernatant was further centrifuged at 17,000g for 20 min to sepa-
rate the mitochondrial fraction. Cytosolic fraction was diluted in
Laemmli buffer and denaturated at 95°C for 10 min. Proteins were sep-
arated by electrophoresis using 10–15% polyacrylamide gradient gels
and transferred onto nitrocellulose membranes. Primary antibodies
are listed below: TSG-6: goat-anti-hTSG-6 (1:80, R&D Systems, RRID:
AB_2240677), cleaved caspase-3: rabbit-anti-caspase-3 (1:1000, Cell
Signaling, RRID: AB_2070042), IBA1: rabbit-anti-IBA1 (1:1000, Wako
Pure Chemical Industries). For quantitative analysis, HRP-linked sec-
ondary antibodies against the speciﬁc host specieswere used, visualized
using Amersham ECL Plus (GE Healthcare) and detected by ChemiDoc
XRS+ System. Data were evaluated densitometrically using ImageLab
software (Bio-Rad).
2.4. Multiplex ELISAs
Bioplex rat cytokine analysis was performed on serum and brain
tissue. Data were acquired using Luminex 200 with IS2.3/
xPONENT3.1 software and further processed with the R package
nCal (Fong and Sebestyen, 2013). Standard curves were ﬁtted by lo-
gistic regression (Ritz and Streibig, 2005) to estimate absolute con-
centration of analytes.
2.5. Real-time PCR
Total cellular RNA was extracted using TRIzol reagent (Invitrogen,
Life Technologies). Further processing included DNAse I reaction of
250–1000 ng RNA per batch and sample (Invitrogen, Life Technologies)
and reverse transcription to cDNA using SuperScript II enzymes
(Invitrogen, Life Technologies). The resulting cDNA was diluted using
equivalent amounts of sterile distilled water. Relative quantiﬁcation of
cDNA amounts was performed using real-time PCR (StepOnePlus, Ap-
plied Biosystems) and the 2−ΔΔCT (Livak and Schmittgen, 2001) meth-
od. The sequence of the TSG-6 forward primer was GTA GGA AGA TAC
TGC GGT GAT GAA, the sequence of the TSG-6 reverse primer was
GAC GGA CGC ATC ACT CAG AA and 6-FAM – TCC AGA AGA CAT CAT
CAG CAC AGG AAA TGT – BHQ1 for the probe (BioTeZ).
2.6. Statistics
Statistical computing was done using R statistical environment
(Team and R Core Team, 2012) and the dedicated integrated devel-
opment environment RStudio. Additional packages used were gdata
(Warnes, and with contributions from Ben Bolker, Gorjanc, G.,
Grothendieck, G., Korosec, A., Lumley, T., MacQueen, D., Magnusson,
A., Rogers, J., Others, 2012), ggplot2 (Wickham, 2009), stringr
(Wickham, 2012) and nCal (Fong and Sebestyen, 2013; Ritz and
Streibig, 2005). Most data were log2 transformed to improve standard
distribution of data. p-Values were calculated using analysis of variance
models ﬁtted into Tukey's Honest Signiﬁcant Differencemethod aswell
as pairwise t-test using the Holm-Bonferroni method for multiple test-
ing (#: p N 0.05, *: p b 0.05, **: p b 0.01, ***: p b 0.001). Graphical presen-
tation was generated using ggplot2.
3. Results
3.1. Developmental regulation of TSG-6 in the neonatal brain
We detected TSG-6 in the healthy neonatal rat brain at both mRNA
and protein level by real-time PCR (Fig. 1) and Western blotting (data
Fig. 1.Developmental expression of TSG-6 mRNA in newborn rat brains. TSG-6 mRNA
is linearly up-regulated from P1 to P15 by about 3-fold. Method: rtPCR, samples:
hemispheres/n = 4–5, treatment: decapitation 1–15 days (P1–P15) after birth,
graphics: points ± CI, statistics: linear regression (y = log2(x)) / coefﬁcient of
determination = 0.9675.
Table 1
p-Values of TSG-6 mRNA expression in different brain regions.
Cortex Hemisphere Striatum
Hemisphere 0.02756 – –
Striatum 0.00025 8.1×10−7 –
Thalamus 2.8×10−8 3.0×10−10 0.00025
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more than 3-fold from P1 to P15. Calculating linear regression revealed
a strong association between TSG-6mRNA expression and day of life.
At the protein level, TSG-6 expression showed high statistical vari-
ability and only weak association with the day of life. TSG-6 expres-
sion in selected brain regions on P6 revealed signiﬁcant differences.
The pattern of local TSG-6 expression was similar at mRNA and pro-
tein level, although differences inmRNA levels were larger (Fig. 2). In
the cortex, expression was lower than in whole hemispheres with
−17% at protein level and −12% at the mRNA level. Lower expres-
sion was also detected in the thalamus showing −30% at protein
level and−63% at the mRNA level. Striatum showed ambivalent ex-
pression with +9% at protein level and−45% at the mRNA level. All
differences betweenmRNA expressions in any brain region were sta-
tistically signiﬁcant (Table 1), while only the differences betweenFig. 2. Expression of TSG-6 mRNA/protein in different brain regions. TSG-6 mRNA and
protein expression varies between different brain regions. It is lower in thalamus, cortex
and striatum than in whole hemispheres with the exception of striatum at protein level.
Method: rtPCR / Western blot, samples: brain regions/n = 5–11, treatment: injection of
sodium chloride 0.9% on P3/decapitation on P6, graphics: errorplots ± CI, statistics:
pairwise t-test/p-values displayed in Tables 1 and 2TSG-6 protein expression in thalamus and in hemispheres/striatum
reached statistical signiﬁcance (Table 2).3.2. Regulation of TSG-6 under inﬂammatory conditions in the neonatal
brain
Administration of LPS to newborn Wistar pups induced an
extensive, systemic inﬂammatory response (Fig. 3), including up-
regulation of pro-inﬂammatory cytokines, anti-inﬂammatory cyto-
kines and chemokines. The immune response peaked between 2 and
8 h after i.p. LPS administration. Interestingly, after 48 h (Fig. 4), the im-
mune response reversed to lower levels than in sham-treated animals,
with serum Interferon-γ and IL-6 being reduced the most to levels of
less than 30% of the controls. In the brain, cytokine levels were below
the detection limit (data not shown). As TSG-6, known for pronounced
anti-inﬂammatory activities, is expressed in the developing brain, we
investigated whether TSG-6 levels in the brain were up-regulated
after i.p. LPS administration. Fig. 5 shows the TSG-6 expression 0–24 h
after LPS stimulus i.p. on P3. At the mRNA level, TSG-6 expression in
the brain was signiﬁcantly up-regulated after LPS exposure. The maxi-
mum expression was reached 4 h after LPS administration with +52%
and returned to normal levels after 12 h. At the protein level, statistical
variability was higher than at the mRNA level and no signiﬁcant differ-
ences in expression levels were detected (data not shown). Later time-
points (P6 + P11 for hemisphere, P6 for brain regions) did not exhibit
signiﬁcant differences of TSG-6 expression in hemispheres, cortex, thal-
amus and striatum at the mRNA level between LPS and sham-treated
animals (data not shown).3.3. Systemic and local effects of repetitive TSG-6 application on preterm
rats under inﬂammatory conditions
Pups which received LPS on P3 and TSG-6 on P3 + P4 were eval-
uated on P5 for cleaved caspase-3 and microglia activation in the
brain and for cytokine levels in serum. Fig. 6 shows the presence of
cleaved caspase-3 in the different treatment groups. LPS exposure
increased levels of cleaved caspase-3 by 3-fold, but additional TSG-
6 administration decreased this up-regulation by about 30%. The
same samples were evaluated for IBA1 (Fig. 7), a marker for activated
microglia (Boche et al., 2013). Its expression was signiﬁcantly up-
regulated by about 50% after LPS and remained unaffected by addi-
tional treatment with TSG-6. Fig. 8 shows the expression of selected
cytokines in serum in the different treatment groups. Interferon-γ,
IL-1β and MIP-3α were highly up-regulated by LPS treatment, but
down-regulated by additional TSG-6 treatment (Interferon-γ: back
to initial value, IL-1β: down-regulated by 25%, MIP-3α: down-
regulated by 70%).Table 2
p-Values of TSG-6 protein expression in different brain regions.
Cortex Hemisphere Striatum
Hemisphere 0.19932 – –
Striatum 0.06828 0.27350 –
Thalamus 0.05096 0.00037 0.00025
Fig. 3. Systemic inﬂammatory response in the ﬁrst 8 h after inﬂammatory stimulus. Cytokine expression is elevated in serum 2–8 h after inﬂammatory stimulus indicating a massive
systemic response. Method: multiplex ELISA, samples: serum/n = 4–5, treatment: NaCl = sodium chloride 0.9% [P3]/LPS = lipopolysaccharide 0.25 mg/kg [P3]/decapitation on P5,
graphics: barplots + CI, statistics: Tukey's honest signiﬁcance test (#: p N 0.05, *: p b 0.05, **: p b 0.01, ***: p b 0.001).
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4.1. Role of TSG-6 in the developing brain
TSG-6 expression in the ﬁrst postnatal days of brain development at
bothmRNA and protein levels (Fig. 1, Fig. 2) suggests that TSG-6may be
important during brain maturation. The linear up-regulation of TSG-6
mRNA between P1 and P15 in the hemispheres and the different levels
of expression in hemispheres, cortex, thalamus and striatum implicate aFig. 4. Systemic inﬂammatory response 48 h after inﬂammatory stimulus. Cytokine expressi
preconditioning effect of LPS on second insults. Method: multiplex ELISA, samples: serum
0.25 mg/kg [P3]/PBS = phosphate buffered saline 2×/d [P3 + P4]/decapitation on P5, graphicshighly regulated mechanism. In contrast, TSG-6 protein levels show
profound variability duringdevelopment fromP1 to P15, but TSG-6 pro-
tein is certainly expressed in the neonatal brain. One possible mecha-
nism of TSG-6 to inﬂuence brain development is its capability to
modify the extracellular matrix. Baranova et al. (2011) revealed that
TSG-6 oligomers cross-link and condense hyaluronan matrices in vitro
under in vivo like conditions. Uniaxial stretching has been postulated
to transform these matrices to ﬁber-like structures. Such ﬁber-like
hyaluronan structures have been found along migratory pathways ofon is decreased in serum 48 h after inﬂammatory stimulus. This could contribute to the
/n = 12–15, treatment: NaCl = sodium chloride 0.9% [P3]/LPS = lipopolysaccharide
: barplots + CI, statistics: pairwise t-test (#: p N 0.05, *: p b 0.05, **: p b 0.01, ***: p b 0.001).
Fig. 5. Expression of TSG-6mRNA in brain hemispheres after inﬂammatory stimulus. TSG-
6mRNA expression is increased in brain hemispheres 4 h after LPS injection and therefore
matching the peak of the systemic inﬂammatory response. Method: rtPCR, samples:
hemispheres/n = 4–7, treatment: NaCl = sodium chloride 0.9% [P3]/LPS =
lipopolysaccharide 0.25 mg/kg [P3]/decapitation on P3 + 0–24 h, graphics: barplots ±
CI, statistics: Tukey's honest signiﬁcance test (**: p b 0.01).
Fig. 7. Expression of IBA1 under inﬂammatory conditions and TSG-6 treatment. IBA1
expression in newborn rat brains, a marker for microglia activation, is increased after
LPS injection. Additional TSG-6 treatment does not alter the level of expression.Method:
Western blot, samples: hemispheres/n = 12–15, treatment: NaCl = sodium chloride
0.9% [P3]/LPS = lipopolysaccharide 0.25 mg/kg [P3]/TSG-6 = TSG-6 2.25 mg/kg 2×/d
[P3 + P4]/PBS = phosphate buffered saline 2×/d [P3 + P4]/decapitation on P5,
graphics: barplots + CI, statistics: pairwise t-test
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drocyte precursor cells (Baier et al., 2007; Gerlach et al., 2010), suggest-
ing a role of TSG-6 during migration of neuronal precursor cells and
maturation of oligodendrocytes. Proving colocalization of TSG-6 with
neuronal or oligodendrocyte precursor cells would support this hypoth-
esis, but we did not achieve a convincing immunohistochemical stain-
ing of TSG-6.
4.2. Role of TSG-6 in developmental inﬂammatory brain injury
Treatment of neonatal Wistar rats with LPS induces pronounced
systemic inﬂammation with activation of a large number of cyto-
kines, peaking after 2–8 h (Fig. 3). Although in-vitro studies of
oligodendrocyte-microglia-co-cultures have shown elevated cyto-
kine gene expression after LPS stimulation (Brehmer et al., 2012)
and in-vivo studies of brain tissue demonstrated elevated cytokine
gene and protein expression after IL-1β stimulation (Adén et al.,Fig. 6. Levels of cleaved caspase-3 under inﬂammatory conditions and TSG-6 treatment.
Cleaved caspase-3 levels in newborn rat brains are increased after LPS injection.
Additional TSG-6 treatment reduces this elevation by about 30%. Method: Western blot,
samples: hemispheres/n = 12–15, treatment: NaCl = sodium chloride 0.9% [P3]/LPS =
lipopolysaccharide 0.25 mg/kg [P3]/TSG-6 = TSG-6 2.25 mg/kg 2×/d [P3 + P4]/PBS =
phosphate buffered saline 2×/d [P3 + P4]/decapitation on P5, graphics: barplots + CI,
statistics: pairwise t-test2010), we did not detect cytokines in the brain at levels above the de-
tection limit of our multiplex ELISA. However, wewere able to show in-
creased microglia activation by detecting elevated IBA1 levels (Fig. 7,
(Boche et al., 2013)). Therefore the lack of cytokine detection in the
brain is most likely due to limited sensitivity of our multiplex ELISA
technique. Later on, systemic inﬂammation is followed by a global de-
crease of cytokines beginning at about 48 h after the inﬂammatory
stimulus (Fig. 4). LPS is known to have a preconditioning effect on sec-
ond insults like ischemia/hypoxia in the neonatal brain at certain doses
and time intervals between the two insults (Mallard and Hagberg,
2007). A reduction in the expression of cytokines after an inﬂammatory
stimulus could contribute to the preconditioning effect. As TSG-6 is an
endogenous, anti-inﬂammatory protein which is expressed upon in-
ﬂammation (Wisniewski et al., 1993; Bayliss et al., 2001; Al'Qteishat
et al., 2006), we analyzed if TSG-6 is also up-regulated in the brain
under inﬂammatory conditions. Fig. 5 shows that TSG-6 gene expres-
sion is signiﬁcantly up-regulated after 4 h and therefore matches the
peak of the systemic cytokine response. In comparison to an adult
model of cerebral ischemia, the up-regulation of TSG-6 in our model is
lower (Lin et al., 2013). This could either be a characteristic of our
model of LPS-induced neuroinﬂammation or the result of a weaker re-
sponse due to the immaturity of the neonatal immune system and
therefore a characteristic of neonatal neuroinﬂammation.
4.3. Therapeutic potential of TSG-6 in developmental inﬂammatory brain
injury
Cleaved caspase-3 is a downstream effector of apoptosis, with
caspase-3 being the ﬁnal target of several apoptosis activating path-
ways. In the brain, it is not only responsible for apoptosis but also
plays a crucial role in reorganizing axonal and dendritic structures, con-
tributes to long term depression (Li et al., 2010) and inhibits long-term
potentiation (Jo et al., 2011). While apoptosis is triggered by wide-
spread cleavage and activation of caspase-3 in the whole cell, neuronal
plasticity is promoted by limited activation of caspase-3 in dendritic re-
gions (Ertürk et al., 2014). Disturbances in these processes can lead to an
extensive malfunction of the CNS, especially during development
(Hyman and Yuan, 2012; Lakhani et al., 2006; Kuida et al., 1996). There-
fore, reduced activation of caspase-3 after administration of LPS and
TSG-6, compared to sole LPS-treatment (Fig. 6) provides ﬁrst evidence
for the neuroprotective potential of TSG-6, raising the question of the
Fig. 8. Systemic inﬂammatory response after inﬂammatory stimulus and TSG-6 treatment. Cytokine expression is elevated in serum 6 h after inﬂammatory stimulus. Additional TSG-6
treatment reduces the elevated levels.Method: multiplex ELISA, samples: serum/n = 3–4, treatment: NaCl = sodium chloride 0.9% [P3]/LPS = lipopolysaccharide 0.25 mg/kg [P3]/TSG-
6 = TSG-6 2.25 mg/kg 2×/d [P3 + P4]/PBS = phosphate buffered saline 2×/d [P3 + P4]/decapitation on P3 + 6 h, graphics: barplots + CI, statistics: pairwise t-test
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achieved at multiple time points, starting by inhibiting the initiation of
the inﬂammatory cascade via TLR-4 (Pålsson-McDermott and O'Neill,
2004), up to modulating local inﬂammatory effects in the brain. In
order to get a ﬁrst indication where TSG-6 might alter our model of in-
ﬂammatory brain damage, we investigated the systemic inﬂammatory
response. It is substantially reduced after TSG-6 treatment exhibiting
signiﬁcantly reduced amounts of pro-inﬂammatory cytokines (IFN-γ,
MIP-3α) in serum (Fig. 8). Therefore TSG-6 reduces the inﬂammatory
cascade before it actually reaches the brain. As TSG-6 might as well
have local effects, we investigated the expression of IBA1, which is a
marker for activated microglia, in the brain (Fig. 7). We detected an in-
creased expression of IBA1 after LPS treatment which was not affected
by additional TSG-6 administration. Still, the consequences of this in-
creased microglia activation remain elusive as IBA1 is just a general
marker of activation and does not provide information about the actual
phenotype of microglia: M1 (classical activation) and M2 (sometimes
subdivided into alternative activation and acquired deactivation)
(Boche et al., 2013; Ito et al., 1998).
5. Conclusion
TSG-6 expression is spatiotemporally regulated in the neonatal
brain. It is up-regulated from P1 to P15 and shows varying expression
in different brain regions. Therefore, according to its functional charac-
teristics, TSG-6 may play a role in oligodendrocytematuration and neu-
ronal precursor cell migration. Furthermore, TSG-6 is up-regulated in
the neonatal brain under inﬂammatory conditions. Exogenous adminis-
tration of rhTSG-6 decreases the systemic inﬂammation and reduces ap-
optosis in the brain, indicating a neuroprotective effect.
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